The Court of Justice of the European Union (CJEU) issued
a decision in the EUROAPTIEKA case on 22 December 2022. In the
decision, the CJEU concluded that a national provision prohibiting
the advertising of medicinal products on the basis of price (by
announcing a promotion or a package sale with other medicines or
products) is compatible with EU law, even when that advertising
does not mention a particular medicine. According to the CJEU,
price-based promotional campaigns do not encourage the rational use
of the medicine, so they should be prohibited by Member
States.
The case dates back to March 2016, when EUROAPTIEKA, a Latvian
company operating in the field of medicinal products, carried out
an advertising campaign in which it advertised a price reduction on
the purchase of any medicine when customers purchased at least
three products. That advertising campaign was prohibited by the
Latvian Public Health Inspectorate. The decision was based on a
national